EDAP Announces University of Washington Medicine to Launch Focal One® Robotic HIFU Program
Brings advanced focal ablation to prostate cancer patients in the Pacific Northwest LYON, France, September 28, 2021 -- EDAP TMS...
Day: September 28, 2021
Cue Biopharma Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT
Research demonstrates that platform technologies generate therapeutic molecules for selective delivery of immune activating signals, such as IL-2, to disease-relevant...
Longeveron Announces Multiple Presentations at the 11th Annual International Conference on Frailty & Sarcopenia Research
MIAMI, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular...
Zogenix Submits Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome
Supplemental New Drug Application (sNDA) submission is supported by existing clinical data, including positive data from Company’s Phase 3 trial,...
Immutep to Present at Healthcare Investor Conferences
Sydney, AUSTRALIA, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology...
Cabaletta Bio to Present at the Chardan 5th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery...
First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis
Preliminary data from prior Phase 1a/2a trial indicated safety of topical formulation of FW-UP and suggested possible favorable efficacy First...
AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal Degeneration
Dr. Rachel Huckfeldt and Dr. Paul Yang to Present 12-Month Findings and Analysis from AGTC’s Clinical TrialsGAINESVILLE, Fla. and CAMBRIDGE, Mass.,...
Psyence Group and Pure Extracts Finalize “Pure Psyence,” A Joint Venture for the Development of Psychedelic Medicinal Mushroom Extracts
A Canadian partnership with international ties to advance the field of psychedelic medicine globally with standardized extractsA leader in naturally-derived...
Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021
- “The Muscle to Move to the Clinic” Event Will Highlight Preclinical Data Supporting Advancement of Dyne’s DM1 and DMD...
Cytokinetics Announces Fourth Annual Communications Fellowship Grant Program Call for Proposals
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases...
Arbutus to Participate in October Investor Conferences
WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on...
Iterum Therapeutics to Present Data at IDWeek 2021
DUBLIN, Ireland and CHICAGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical...
Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD
55% of GB-102 1mg patients in Extension Study experienced duration of 12+ months, while maintaining their visual acuity and central retinal thickness73% reduction of injection burden...
Kraig Biocraft Laboratories Prepares for Challenge Testing of Disease Resistant Silkworm Lines
Immunity enhanced silkworms provide licensing opportunities into the broader $14 B1 silk industry ANN ARBOR, Mich., Sept. 28, 2021 (GLOBE...
Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas
HOUSTON, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines...
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
Mean weight loss of 10.3% achieved in subjects receiving 1.8 mg dosePemvidutide was well-tolerated without the need for dose titration...
TScan Therapeutics to Participate in the Chardan 5th Annual Genetic Medicines Conference
WALTHAM, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development...
PROCEPT BioRobotics Corporation Announces Cigna Adds Aquablation Therapy to its Coverage Policy
REDWOOD CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on...
Cybrexa Therapeutics to Present at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
NEW HAVEN, Conn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of...
